We present a brief review of pregnancy induced hypertension (PIH) guidelines provided by the Japan Society for Study of Hypertension in Pregnancy (JSSHP) in 2009. This review aims to compare the Japanese standards of diagnosis, treatment, and management of hypertensive disorders in pregnancy with those of other countries, as well as to present a resource for Japanese clinical studies or case reports published internationally.
Foreword
This article is a brief review of pregnancy induced hypertension (PIH) guidelines provided by the Japan Society for Study of Hypertension in Pregnancy (JSSHP) in 2009. 1) The Japanese criteria are stated in the original guidelines in Outline of Definition and Classification of "Pregnancy induced Hypertension (PIH)".
2) Any errors in translation are the responsibility of the author, and not the JSSHP. As such, if any discrepancies exist between the original Japanese guidelines and this article, please defer to the original Japanese guidelines, as they represent the accurate version. The original guidelines are currently being reviewed such that an updated version will be published in 2014.
We present this brief review in order to compare Japanese standards of diagnosis, treatment, and management of hypertensive disorders in pregnancy with those of other countries, and with standards set by the International Society for the Study of Hypertension in Pregnancy (ISSHP). We also anticipate that it will serve as a valuable research tool, as Japanese clinical studies and case reports are conducted and published internationally. CQ 6: How should fetal well-being be assessed in patients with PIH?
1. In cases of fetal growth restriction, a cardiotocogram (CTG) should be initiated during the second trimester of pregnancy (e.g., 26-28 weeks GA). 2. CTG and a biophysical profile score assessment 4) should be performed twice a week. These should be performed every day for patients with severe preeclampsia* before 32 weeks GA. *: Defined as PIH ≥ 160 mmHg for systolic blood pressure or ≥ 110 mmHg for diastolic blood pressure, and proteinuria over 2 g/day.
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CQ 7: How should fetal well-being be assessed by ultrasonography in patients with PIH?
1. Fetal growth should be assessed starting at 18 or 20 weeks GA in hypertensive pregnancies. 2. In patients with PIH, fetal growth should be monitored every 2 weeks.
Umbilical artery Doppler flow is recommended for
cases in which fetal growth restriction occurs. 4. Growth arrest of biparietal diameter and head circumference for 2 weeks necessitates discussion regarding termination of the pregnancy.
CQ 8: How should a convulsion attack in pregnancy be assessed and treated?
1. have a higher risk for developing PIH. 4. Restriction of salt intake to < 10 g/day is recommended to prevent PIH. However, there is no evidence to support dietary restrictions, supplement use, or plasma volume expansion as a means to prevent PIH. *: Defined as PIH with blood pressure ≥ 160 mmHg for systolic or ≥ 110 mmHg for diastolic.
1,2)

